<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00194649</url>
  </required_header>
  <id_info>
    <org_study_id>04-3806-D</org_study_id>
    <secondary_id>U54HD042454</secondary_id>
    <nct_id>NCT00194649</nct_id>
  </id_info>
  <brief_title>Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)</brief_title>
  <acronym>MIG-2</acronym>
  <official_title>Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to help in the development of safe, effective and
      reversible male contraception. We are examining the impact of the drug Miglustat on sperm
      production in normal men.

      We want to see if Miglustat will inhibit sperm production in men and act as a reversible male
      contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of
      sperm production. We believe Miglustat may have some potential as a safe, reversible male
      contraceptive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glycosphingolipids (GSL) are a main constituent of the sperm cell membrane in mammals. Male
      mice deficient in enzymes involved in GSL synthesis have severely impaired fertility and
      knockout mice are infertile. Recently, it was demonstrated that administration to mice of an
      inhibitor of ceramide-specific glycosyltransferase, the first step in the biosynthetic
      pathway of GSL formation, resulted in reversible infertility without discernable adverse side
      effects. This inhibitor was Miglustat, which is an alkylated imino sugar. The impact of
      Miglustat therapy on human spermatogenesis is unknown. If the effects on sperm morphology and
      motility are similar to those observed in mice, Miglustat or other GSL inhibitors might have
      potential utility as non-hormonal male contraceptives.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The impact of GSL inhibition on human spermatogenesis, if impairment is seen with Miglustat administration, larger contraceptive efficacy studies of Miglustat or other inhibitors of GSL's will be performed.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg Miglustat BID (twice daily) for six weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miglustat (Zavesca)</intervention_name>
    <description>100 mg Miglustat BID (twice daily) for six weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zavseca</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male, normal lab test

        Exclusion Criteria:

          -  Abnormal lab test, history or evidence of significant chronic or acute medical
             illness, previous or current ethanol or anabolic steroid abuse.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Amory</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>http://depts.washington.edu/popctr</description>
  </link>
  <reference>
    <citation>Takamiya K, Yamamoto A, Furukawa K, Zhao J, Fukumoto S, Yamashiro S, Okada M, Haraguchi M, Shin M, Kishikawa M, Shiku H, Aizawa S, Furukawa K. Complex gangliosides are essential in spermatogenesis of mice: possible roles in the transport of testosterone. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12147-52.</citation>
    <PMID>9770454</PMID>
  </reference>
  <reference>
    <citation>Ritter G, Krause W, Geyer R, Stirm S, Wiegandt H. Glycosphingolipid composition of human semen. Arch Biochem Biophys. 1987 Sep;257(2):370-8.</citation>
    <PMID>3662530</PMID>
  </reference>
  <reference>
    <citation>Fujimoto H, Tadano-Aritomi K, Tokumasu A, Ito K, Hikita T, Suzuki K, Ishizuka I. Requirement of seminolipid in spermatogenesis revealed by UDP-galactose: Ceramide galactosyltransferase-deficient mice. J Biol Chem. 2000 Jul 28;275(30):22623-6.</citation>
    <PMID>10801776</PMID>
  </reference>
  <reference>
    <citation>Honke K, Hirahara Y, Dupree J, Suzuki K, Popko B, Fukushima K, Fukushima J, Nagasawa T, Yoshida N, Wada Y, Taniguchi N. Paranodal junction formation and spermatogenesis require sulfoglycolipids. Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4227-32. Epub 2002 Mar 26.</citation>
    <PMID>11917099</PMID>
  </reference>
  <reference>
    <citation>Platt FM, Neises GR, Karlsson GB, Dwek RA, Butters TD. N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem. 1994 Oct 28;269(43):27108-14.</citation>
    <PMID>7929454</PMID>
  </reference>
  <reference>
    <citation>van der Spoel AC, Jeyakumar M, Butters TD, Charlton HM, Moore HD, Dwek RA, Platt FM. Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17173-8. Epub 2002 Dec 11.</citation>
    <PMID>12477936</PMID>
  </reference>
  <reference>
    <citation>Beutler E. Gaucher disease. Curr Opin Hematol. 1997 Jan;4(1):19-23. Review.</citation>
    <PMID>9050375</PMID>
  </reference>
  <results_reference>
    <citation>Amory JK, Muller CH, Page ST, Leifke E, Pagel ER, Bhandari A, Subramanyam B, Bone W, Radlmaier A, Bremner WJ. Miglustat has no apparent effect on spermatogenesis in normal men. Hum Reprod. 2007 Mar;22(3):702-7. Epub 2006 Oct 25.</citation>
    <PMID>17067996</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 18, 2008</last_update_submitted>
  <last_update_submitted_qc>September 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>John K Amory, MD, MPH</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>Glycosphingolipids (GSL)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miglustat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

